Preferred Label : Serplulimab;

NCIt definition : A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.;

UNII : S3GQZ2K36V;

CAS number : 2231029-82-4;

Molecule name : HLX-10; HLX 10;

NCI Metathesaurus CUI : CL935905;

Codes from synonyms : 35064;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/hetronifly
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Serplulimab
Serplulimab
drug approval
europe
antibodies, monoclonal
antibodies, monoclonal
serplulimab
small cell lung carcinoma
neoplasm metastasis
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
carboplatin
etoposide
infusions, intravenous
programmed cell death 1 receptor
risk management
product surveillance, postmarketing
Extensive Stage Lung Small Cell Carcinoma
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical

---
Nous contacter.
01/06/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.